Armata AP-SA02 phage cocktail hits primary endpoint in Phase 2a S. aureus bacteremia trial

Armata Pharmaceuticals, Inc.

Day 12 clinical response 88% AP-SA02 vs 58% placebo (p=0.047) by blinded investigators; 83% vs 58% by adjudication committee.
Zero non-response/relapse in AP-SA02 arm at one week post-BAT and EOS vs ~25% placebo (p<0.025).
AP-SA02 well-tolerated; no serious adverse events related to study drug; TEAEs 6% AP-SA02 vs 0% placebo.
Armata plans to initiate a pivotal Phase 3 superiority trial in 2026, subject to FDA feedback.
Defined phage variants in AP-SA02 show intrinsic adaptive mechanism to patient isolates, may enhance efficacy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.